Despite a high profile legal wrangle with FTC and with the New York Attorney General, memory support supplement manufacturer Quincy Bioscience has enough revenue in the tank to afford a high-dollar sponsorship of a NASCAR racing team.
Nutraceutical International Corporation’s longtime aggressive acquisition strategy has borne the ultimate fruit in the announcement today that the company will be sold to a private equity firm for $446 million.
ChromaDex has reported a rapid rise in sales driven mainly by its Niagen ingredient. But the company continues to post losses, and the stock price has failed to recover from a steep slide more than nine months ago.
Company to sell 60% stake in Dairy Ireland to Irish co-op